zejula
glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastiske midler - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.
akeega
janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatic neoplasmer, kastration-resistent - antineoplastiske midler - treatment of adult patients with prostate cancer.
verapamilhydrochlorid "2care4" 240 mg depottabletter
2care4 aps - verapamilhydrochlorid - depottabletter - 240 mg
verapamil "hexal" 120 mg filmovertrukne tabletter
hexal a/s - verapamilhydrochlorid - filmovertrukne tabletter - 120 mg
verapamil "hexal" 40 mg filmovertrukne tabletter
hexal a/s - verapamilhydrochlorid - filmovertrukne tabletter - 40 mg
verapamil "hexal" 80 mg filmovertrukne tabletter
hexal a/s - verapamilhydrochlorid - filmovertrukne tabletter - 80 mg
verapamil "nordic prime" 80 mg filmovertrukne tabletter
nordic prime aps - verapamilhydrochlorid - filmovertrukne tabletter - 80 mg
verapamil "2care4" 120 mg filmovertrukne tabletter
2care4 aps - verapamilhydrochlorid - filmovertrukne tabletter - 120 mg
verapamil "nordic prime" 120 mg filmovertrukne tabletter
nordic prime aps - verapamilhydrochlorid - filmovertrukne tabletter - 120 mg
rubraca
pharmaand gmbh - rucaparib camsylate - Æggestokkene neoplasmer - antineoplastiske midler - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca er angivet som monoterapi til vedligeholdelse behandling af voksne patienter med platin-følsomme gået high-grade epitelial ovariecancer, æggeleder, eller primær peritoneal cancer, der er i reaktion (hel eller delvis) til platin-baseret kemoterapi.